Pulmonary Fibrosis

Pulmonary fibrosis is a chronic, progressive, and irreversible interstitial lung disease characterized by excessive deposition of extracellular matrix components, particularly collagen, within the alveolar walls and interstitium, leading to architectural distortion, reduced lung compliance, and impaired gas exchange. In veterinary medicine, it is most commonly recognized as a distinct clinical entity in West Highland White Terriers (WHWTs), where it is termed canine idiopathic pulmonary fibrosis (CIPF), but it can also occur in other breeds and in cats, often secondary to chronic inflammation, infection, or environmental insults. The disease is classified based on etiology (idiopathic vs. secondary), histopathological pattern (usual interstitial pneumonia-like, nonspecific interstitial pneumonia, etc.), and clinical stage (early, moderate, advanced). The hallmark is restrictive lung physiology, with decreased tidal volume and increased respiratory effort, ultimately leading to hypoxemia, respiratory failure, and cor pulmonale.

The etiology of pulmonary fibrosis in animals is often multifactorial. In dogs, the most well-documented form is idiopathic, with a strong breed predisposition in West Highland White Terriers, suggesting a genetic basis. Suspected triggers include chronic inhalation of irritants (e.g., cigarette smoke, dust, allergens), viral or bacterial infections (e.g., canine distemper virus, Bordetella bronchiseptica), and gastroesophageal reflux with chronic aspiration. In cats, pulmonary fibrosis may be associated with chronic allergic bronchitis, asthma, or parasitic infections (e.g., Aelurostrongylus abstrusus). Secondary causes include connective tissue disorders (e.g., systemic lupus erythematosus), drug-induced fibrosis (e.g., bleomycin, cyclophosphamide), and radiation therapy. Environmental factors such as exposure to silica, asbestos, or organic dusts have been implicated in humans and may play a role in animals. The molecular pathogenesis involves alveolar epithelial injury, activation of fibroblasts and myofibroblasts, and dysregulated repair processes, with key cytokines including transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and tumor necrosis factor-alpha (TNF-α).

Pulmonary fibrosis is most commonly reported in middle-aged to older dogs, with a median age of onset around 8-10 years. West Highland White Terriers are overwhelmingly overrepresented, with a reported prevalence of up to 30% in some populations, and a clear genetic predisposition is suspected, possibly involving mutations in genes related to surfactant proteins or telomerase. Other breeds that may be affected include the Staffordshire Bull Terrier, Border Collie, and various terrier breeds, but with much lower incidence. There is no strong sex predilection, though some studies suggest a slight female predominance. In cats, pulmonary fibrosis is rare but can occur in any breed, often secondary to chronic lower airway disease. Geographic distribution is not well-defined, but environmental factors such as air pollution or secondhand smoke may increase risk. The disease is progressive and ultimately fatal, with a median survival time of 6-12 months after diagnosis in symptomatic dogs.

The pathophysiology of pulmonary fibrosis involves a complex cascade of events initiated by repetitive alveolar epithelial injury. The injured alveolar epithelium releases pro-inflammatory and profibrotic cytokines, including TGF-β, which recruits inflammatory cells (macrophages, neutrophils, lymphocytes) and activates resident fibroblasts. These fibroblasts differentiate into myofibroblasts, which are contractile and produce excessive collagen and other extracellular matrix components. The accumulation of matrix proteins in the interstitium and alveolar walls leads to thickening and stiffening of the lung parenchyma, reducing compliance and impairing gas exchange. As the disease progresses, there is architectural distortion with honeycombing, traction bronchiectasis, and loss of alveolar-capillary units. The restrictive pattern results in decreased lung volumes, increased work of breathing, and ventilation-perfusion mismatch, leading to hypoxemia. Pulmonary hypertension may develop due to chronic hypoxemia and vascular remodeling, culminating in right-sided heart failure (cor pulmonale). The disease is typically progressive, with exacerbations triggered by infections or stress.

Predisposing factors for pulmonary fibrosis include genetic susceptibility, particularly in West Highland White Terriers, where an autosomal recessive mode of inheritance has been proposed. Age is a significant factor, as the disease is more common in older animals. Environmental exposures, such as secondhand tobacco smoke, dust, and air pollution, may increase the risk. Chronic respiratory infections or inflammatory conditions, such as chronic bronchitis or asthma, can predispose to fibrosis. Gastroesophageal reflux with chronic aspiration is a recognized risk factor in dogs. Certain medications, including chemotherapeutic agents like bleomycin and cyclophosphamide, can induce pulmonary fibrosis. Additionally, underlying systemic inflammatory or autoimmune diseases may contribute. Obesity and poor nutritional status may exacerbate the clinical course.

Clinical signs of pulmonary fibrosis are often insidious and progressive. Early signs include exercise intolerance, mild tachypnea, and a dry, non-productive cough. As the disease advances, affected animals develop increased respiratory effort, characterized by rapid, shallow breathing, and may exhibit orthopnea or a 'panting' pattern. Crackles may be auscultated on lung auscultation, particularly in the caudodorsal lung fields. In advanced stages, cyanosis, syncope, and signs of right-sided heart failure (e.g., ascites, jugular distension) may occur. Cats may present with similar signs, often with a history of chronic coughing or wheezing. Systemic signs such as weight loss, lethargy, and anorexia are common. The disease is progressive, and acute exacerbations can be triggered by stress, infection, or exercise.

Differential diagnoses for pulmonary fibrosis include: 1) Chronic bronchitis – characterized by a productive cough, responsive to bronchodilators and corticosteroids, with radiographic evidence of bronchial thickening rather than interstitial fibrosis. 2) Eosinophilic bronchopneumopathy – associated with peripheral eosinophilia and eosinophilic infiltrates on cytology, responsive to glucocorticoids. 3) Pulmonary neoplasia (e.g., bronchoalveolar carcinoma) – may present with nodular interstitial pattern on radiographs, and diagnosis via cytology or histopathology. 4) Congestive heart failure – typically shows cardiomegaly, pulmonary venous congestion, and pleural effusion on radiographs, with echocardiographic evidence of cardiac dysfunction. 5) Infectious pneumonia (bacterial, fungal, parasitic) – often presents with fever, leukocytosis, and alveolar infiltrates, and responds to antimicrobial therapy. 6) Pulmonary thromboembolism – acute onset of dyspnea, with risk factors such as hyperadrenocorticism or heart disease, and imaging findings may be normal or show oligemia. 7) Interstitial lung diseases of other etiologies, such as lymphocytic interstitial pneumonia or bronchiolitis obliterans with organizing pneumonia (BOOP). Definitive diagnosis often requires advanced imaging (CT) and histopathology.

The diagnostic algorithm for pulmonary fibrosis begins with a thorough history and physical examination, with emphasis on breed, age, and clinical signs. Baseline diagnostics include complete blood count, serum biochemistry, urinalysis, and thoracic radiographs. Radiographic findings may show a diffuse interstitial pattern, often with a bronchointerstitial pattern, and in advanced cases, a honeycomb appearance. If radiographs are inconclusive, high-resolution computed tomography (HRCT) is the imaging modality of choice, revealing ground-glass opacities, reticular patterns, traction bronchiectasis, and honeycombing. Arterial blood gas analysis typically shows hypoxemia with a normal or decreased PaCO2. Bronchoalveolar lavage (BAL) may be performed to rule out infectious or inflammatory causes; in pulmonary fibrosis, BAL fluid is often non-diagnostic but may show increased neutrophils or macrophages. Definitive diagnosis requires histopathological examination of lung tissue obtained via surgical biopsy or, less commonly, transbronchial biopsy. However, in cases with typical clinical signs, breed predisposition, and characteristic HRCT findings, a presumptive diagnosis may be made without biopsy. Additional tests may include echocardiography to assess for pulmonary hypertension and right heart function.

Laboratory findings in pulmonary fibrosis are often non-specific. Complete blood count may be normal or show mild leukocytosis due to stress or concurrent inflammation. Serum biochemistry is usually unremarkable, but may reveal mild elevations in liver enzymes or globulins. Arterial blood gas analysis typically demonstrates hypoxemia (decreased PaO2) with a normal or decreased PaCO2, and an increased alveolar-arterial oxygen gradient. Pulse oximetry may show decreased SpO2. In cases with pulmonary hypertension, echocardiography may reveal elevated right ventricular systolic pressure. Biomarkers such as NT-proBNP may be elevated if cor pulmonale is present. Bronchoalveolar lavage fluid analysis may show increased total cell count, with a predominance of macrophages and occasionally neutrophils or eosinophils, but is not diagnostic. Genetic testing for known mutations in WHWTs is not yet commercially available but may be offered in research settings.

Thoracic radiography in pulmonary fibrosis typically reveals a diffuse, unstructured interstitial pattern, often most prominent in the caudodorsal lung fields. In early stages, the pattern may be subtle, and a bronchointerstitial pattern may be seen. As the disease progresses, a reticulonodular pattern or honeycombing may develop, and there may be evidence of pulmonary hypertension, such as right-sided cardiomegaly and pulmonary artery enlargement. High-resolution computed tomography (HRCT) is the most sensitive imaging modality, showing ground-glass opacities, reticular opacities, traction bronchiectasis, and honeycombing, predominantly in the peripheral and subpleural regions. HRCT can also help differentiate pulmonary fibrosis from other interstitial lung diseases. Echocardiography is useful to evaluate for pulmonary hypertension and right heart enlargement, which are common complications. In some cases, fluoroscopy may be used to assess diaphragmatic motion, but it is not routinely performed.

Cytological evaluation of bronchoalveolar lavage fluid (BAL) in pulmonary fibrosis is often non-specific, but may show increased cellularity with a predominance of alveolar macrophages, and occasionally neutrophils or eosinophils. There are no pathognomonic cytological features. Histopathological examination of lung tissue is the gold standard for diagnosis. In canine idiopathic pulmonary fibrosis, the characteristic pattern is that of usual interstitial pneumonia (UIP), with patchy interstitial fibrosis, alveolar septal thickening, type II pneumocyte hyperplasia, and the presence of fibroblastic foci. Honeycombing, traction bronchiectasis, and smooth muscle hyperplasia may be seen in advanced cases. Special stains such as Masson's trichrome can highlight collagen deposition. In cats, a similar pattern may be observed, but there may be more prominent lymphocytic inflammation. Histopathology is essential to rule out other interstitial lung diseases, such as lymphocytic interstitial pneumonia or neoplasia.

There is no curative treatment for pulmonary fibrosis; therapy is aimed at managing clinical signs, slowing disease progression, and improving quality of life. The mainstay of treatment is anti-inflammatory and immunosuppressive doses of corticosteroids, such as prednisone or prednisolone, at 0.5-1 mg/kg PO q12h, tapering to the lowest effective dose. In dogs that do not respond to corticosteroids alone, adjunctive immunosuppressive agents such as cyclosporine (5-10 mg/kg PO q24h) or azathioprine (2 mg/kg PO q24h) may be considered, though evidence of efficacy is limited. Bronchodilators, such as theophylline (10-20 mg/kg PO q12h) or terbutaline (0.01-0.02 mg/kg SC or PO q8h), may help alleviate bronchospasm and improve airflow. Antitussives, such as hydrocodone (0.22 mg/kg PO q8-12h) or butorphanol (0.05-0.1 mg/kg PO q8-12h), may be used to control coughing. Oxygen supplementation is indicated during hypoxemic episodes. In cases with pulmonary hypertension, sildenafil (1-2 mg/kg PO q8h) may be used to reduce pulmonary arterial pressure. Management of concurrent conditions, such as gastroesophageal reflux, is important. Nutritional support and weight management are essential. In severe cases, the prognosis is poor, and euthanasia may be considered when quality of life deteriorates.

The prognosis for pulmonary fibrosis is generally poor, with a progressive and ultimately fatal course. Median survival time in dogs after diagnosis is reported to be 6-12 months, though some may live longer with supportive care. Factors associated with a worse prognosis include advanced age, severe hypoxemia, presence of pulmonary hypertension, and lack of response to corticosteroid therapy. Cats may have a slightly better prognosis if the underlying cause is treatable, but idiopathic cases carry a guarded prognosis. The disease is typically slowly progressive, but acute exacerbations can occur, leading to rapid deterioration. Owners should be counseled about the chronic nature of the disease and the limitations of treatment.

Follow-up for patients with pulmonary fibrosis should include regular re-evaluations every 1-3 months, depending on clinical status. At each visit, a thorough physical examination, including respiratory rate and effort, and thoracic auscultation should be performed. Pulse oximetry or arterial blood gas analysis should be repeated to monitor oxygenation. Thoracic radiographs may be repeated every 3-6 months to assess progression, though HRCT is more sensitive but may be limited by cost and need for anesthesia. Echocardiography should be performed if pulmonary hypertension is suspected or if clinical signs of right heart failure develop. Blood work, including CBC and biochemistry, should be monitored periodically, especially if immunosuppressive therapy is used. Owners should be educated to monitor for signs of respiratory distress and to seek immediate veterinary care if they occur. Adjustments to medication dosages should be made based on clinical response and side effects.

Pearls: 1) In a West Highland White Terrier with chronic cough and exercise intolerance, pulmonary fibrosis should be a primary differential. 2) Crackles on thoracic auscultation are a common finding and may be mistaken for pneumonia. 3) HRCT is the most sensitive imaging modality for diagnosing pulmonary fibrosis and can help avoid unnecessary lung biopsy. 4) Corticosteroids may provide temporary relief but do not halt disease progression. 5) Early recognition of pulmonary hypertension and treatment with sildenafil may improve quality of life. Pitfalls: 1) Misdiagnosing pulmonary fibrosis as chronic bronchitis or asthma, leading to inappropriate treatment. 2) Overlooking secondary causes such as gastroesophageal reflux, which may exacerbate the disease. 3) Using high-dose corticosteroids for prolonged periods without monitoring for side effects. 4) Failing to recommend oxygen supplementation during hypoxemic episodes. 5) Not discussing the poor prognosis with owners, leading to unrealistic expectations.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols may be considered for pulmonary fibrosis: 1) Prednisone/Prednisolone: Dogs: 0.5-1 mg/kg PO q12h for 2-4 weeks, then taper to 0.5-1 mg/kg PO q48h or the lowest effective dose. Cats: 1-2 mg/kg PO q12h, tapering similarly. 2) Cyclosporine (modified): Dogs: 5-10 mg/kg PO q24h, adjust based on trough levels (target 400-600 ng/mL). Cats: 5-7 mg/kg PO q24h. 3) Azathioprine: Dogs: 2 mg/kg PO q24h for 7-10 days, then q48h. Cats: 0.3-0.6 mg/kg PO q48h (use with caution). 4) Theophylline (extended-release): Dogs: 10-20 mg/kg PO q12h. Cats: 15-20 mg/kg PO q24h. 5) Terbutaline: Dogs: 0.01-0.02 mg/kg SC or PO q8h. Cats: 0.01-0.02 mg/kg PO q8h. 6) Sildenafil: Dogs: 1-2 mg/kg PO q8h. Cats: 1-2 mg/kg PO q8h. 7) Hydrocodone bitartrate: Dogs: 0.22 mg/kg PO q8-12h. Cats: 0.05-0.1 mg/kg PO q8-12h (use with caution). 8) Butorphanol: Dogs: 0.05-0.1 mg/kg PO q8-12h. Cats: 0.05-0.1 mg/kg PO q8-12h. All dosages should be adjusted based on renal or hepatic function, and drug interactions should be considered, especially with corticosteroids and cyclosporine.

Evidence-based literature on pulmonary fibrosis in veterinary medicine is limited, but several key studies have been published. A landmark study by Heikkilä et al. (2011) described the clinical, radiographic, and histopathological features of canine idiopathic pulmonary fibrosis in West Highland White Terriers, establishing the breed predisposition and characteristic findings. Another study by Johnson et al. (1999) evaluated the use of high-resolution computed tomography in diagnosing pulmonary fibrosis in dogs, demonstrating its superiority over radiography. Regarding treatment, a retrospective study by Corcoran et al. (1999) reported that corticosteroids provided symptomatic improvement in some dogs but did not alter the long-term outcome. More recent research has focused on the role of TGF-β and other profibrotic cytokines, with potential future therapies targeting these pathways. In cats, a case series by Norris et al. (2002) described pulmonary fibrosis as a cause of chronic respiratory disease. Consensus guidelines from the ACVIM on canine and feline respiratory diseases recommend a stepwise diagnostic approach and emphasize the need for further research into effective therapies.